Rated “Outperform” with price target of €7.10 Analysts cite $60 million BARDA contract for Crossject’s ZEPIZURE® as validation of platform…
STOCKHOLM, SWEDEN / ACCESSWIRE / November 28, 2023 / AlzeCure Pharma (STO:ALZCUR)(FRA:AC6) AlzeCure Pharma AB (publ) (FN STO: ALZCUR), a…
STOCKHOLM, SWEDEN / ACCESSWIRE / November 28, 2023 / Promore Pharma (STO:PROMO)(FRA:8T0)July to SeptemberNet sales amounted to MSEK 0 (0)Net…
New offering provides an all-in-one AI platform optimized for mammography, that seamlessly integrates artificial intelligence (AI) applications from iCAD to…
SAN MATEO, Calif.--(BUSINESS WIRE)--Model N, Inc. (NYSE: MODN), the leader in revenue optimization and compliance today announced that Model N…
The ICONIC program now includes four Phase 3 studies evaluating JNJ-2113; Co-primary endpoints for all four studies are PASI-90 and/or…
ZURICH, SWITZERLAND / ACCESSWIRE / November 27, 2023 / NLS Pharmaceutics Ltd. (Nasdaq:NLSP, NLSPW) ("NLS" or the "Company"), a Swiss…
Phase 1 ex-US trial achieved primary objective of predictable pharmacokinetic profiling with favorable safety and tolerabilityCompany expects to engage FDA…
TORONTO, ON / ACCESSWIRE / November 27, 2023 / FSD Pharma Inc. (NASDAQ:HUGE)(CSE:HUGE)(FRA:0K9A) ("FSD Pharma" or the "Company"), a biopharmaceutical…
Clearmind Medicine CEO, Dr. Adi Zuloff-Shani, and MAPS founder and psychedelic sector pioneer, Rick Doblin, will discuss the growing and…